U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499440) titled 'Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study' on March 24.
Brief Summary: The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
PTSD
Mental Illness
Intervention:
DRUG: HB-1
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet. The two HB-1 doses for this study include 64/192 and 86/258 telmisartan/verapamil extended release, using unique...